Recent developments in the medical treatment of thyroid eye disease

Orbit

Volumn 25, Issue 2, 2006, Pages 117-122

  Krassas, G ^a   Boboridis, K ^b  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Analogs; Corticosteroids; Medical treatment; Radiotherapy; Somatostatin; Thyroid eye disease

Indexed keywords

GLUCOCORTICOID; SOMATOSTATIN DERIVATIVE;

ARTICLE; CLINICAL TRIAL; ENDOCRINE OPHTHALMOPATHY; HUMAN; LIVER FUNCTION; LIVER TOXICITY; PATIENT MONITORING; RISK FACTOR;

GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; ORBIT; SOMATOSTATIN;

EID: 33745025258     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.1080/01676830600575576     Document Type: Article

References (30)

1. Bartalena L. Editorial: Glucocorticoids for Graves' ophthalmopathy: How and when. J Clin Endocrinol Metab. 2005a;90:5497-5499.
2. Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349-1352.
3. Bartalena L, Marcocci C, Bogazzi F, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab. 2005b;90:5321-5323.
4. Bartalena L, Marcocci C, Gorman CA, et al. Orbital radiotherapy for Graves' ophthalmopathy: Useful or useless? Safe or dangerous? J Endocrinol Invest. 2003;26:5-16.
5. Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves' ophthalmopathy: Do they bounce off like a rubber bullet? J Clin Endocrinol Metab. 2004;89:5908-5909.
6. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: Reality and perspectives. Endocr Rev. 2000;21:168-199.
7. Burch HB, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747-793.
8. Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ. 2004;329:385-390.
9. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89:5910-5915.
10. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001;108:1523-1534.
11. Gorman CA, Garrity JA, Fatourechi V, et al. The aftermath of orbital radiotherapy for graves' ophthalmopathy. Ophthalmology. 2002;109:2100-2107.
12. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005;90:5234-5240.
13. Kahaly GJ, Rosier HP, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: A randomized, single blind trial. J Clin Endocrinol Metab. 2000;85:102-108.
14. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: An overview of current concepts. Eur J Endocrinol. 2001;144:311-318.
15. Krassas GE. Somatostatin analogs: A new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004;27:281-287.
16. Marcocci C, Bartalena L, Marino M, et al. Current medical management of Graves ophthalmopathy. Ophthal Plast Reconstr Surg. 2002;18:402-408.
17. Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab. 2003;88:3561-3566.
18. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86:3562-3567.
19. Marino M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid. 2004;14:403-406.
20. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves' orbitopathy: Randomised placebo-controlled study. Lancet. 2000;355:1505-1509.
21. Perros P, Kendall-Taylor P, Neoh C, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmology. J Clin Endocrinol Metab. 2005;90:5321-5323.
22. Perros P, Krassas GE. Orbital irradiation for thyroid-associated orbitopathy: Conventional dose, low dose or no dose? Clin Endocrinol (Oxf). 2002;56:689-691.
23. Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15-20.
24. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA. 1993;269:479-482.
25. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves' ophthalmopathy and smoking. Lancet. 1990;335:1261-1263.
26. Steinsapir KD, Goldberg RA. Orbital radiation therapy for Graves' ophthalmopathy. Ophthalmology. 2003;110:451-452.
27. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733-1738.
28. Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med. 1998;338:121-122.
29. Wiersinga WM, Prummel MF. Pathogenesis of Graves' ophthalmopathy-current understanding. J Clin Endocrinol Metab. 2001;86:501-503.
30. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005;90:841-848.